Navigation Links
Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options

VIENNA, Sept. 16 /PRNewswire/ -- Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced results from an analysis of the cost-effectiveness of three different inhaled corticosteroids (ICSs) in a "real-life" asthmatic population. The study found QVAR(R) (beclomethasone dipropionate HFA), an ICS that is able to effectively treat both large and small airway inflammation, to be on average more effective than CFC-beclomethasone dipropionate (BDP) and fluticasone propionate (FP), and intermediary in cost between the two. This "real-life" study followed more than 4,000 asthma patients in the UK for 12 months, and data was presented at the European Respiratory Society's Annual Congress in Vienna, Austria.

Several short-term, randomized controlled trials (RCTs) demonstrated that QVAR(R) and other ICS therapies, including CFC-BDP and FP metered dose inhalers (pMDI), are efficacious. This year-long "real-life" study was designed to assess the cost-effectiveness of QVAR(R) compared to other ICS therapies in patients identified from the UK General Practice Research Database (GPRD), the world's largest primary care computerized database of anonymized longitudinal medical records. This "real-life" analysis showed that the choice of ICS may impact overall asthma control in the real world, including asthma exacerbation rates.

"ICSs are considered the most effective anti-inflammatory therapy for persistent asthma and are the preferred treatment for initiating maintenance therapy. However, the cost of ICS therapy can be quite high," said David Price, GPAG professor of primary care medicine, University of Aberdeen's Center of Academic Care and lead investigator of the study. "QVAR(R) was on average more cost-effective than fluticasone, and more effective than CFC-beclomethasone dipropionate, although CFC-beclomethasone dipropionate was lowest in cost."

Professor Price added, "The asthma control findings may support that the fine particle size of QVAR(R) distributes medication throughout the entire lung while allowing for more effective penetration into small airways than other ICSs. Research has shown that the 1.1 micrometer mass median aerodynamic diameter (MMAD) of QVAR(R) allows for more effective penetration of the agent into small airways, with lung deposition of up to 58% as compared with 12%-13% with fluticasone CFC."

Teva offers QVAR(R) in the U.S., UK, France, several other European countries as well as Israel. In Germany QVAR(R) is sold under the brand name Ventolair(R) and in the Scandinavian countries QVAR(R) is sold under the brand name Aerobec(R).

About the Study

With the aim of comparing cost-effectiveness for QVAR(R) versus CFC-BDP and FP delivered via pressurized metered dose inhalers in asthmatic patients, investigators identified 4,133 patients (8% QVAR(R), 15% FP, 77% BDP-CFC) from among 450 primary care practices throughout the UK in the GPRD who had increases in ICS use between January 1997 - June 2006. Included patients were age 5-60 years.

A cost-effectiveness analysis, performed from a UK National Health Service perspective, compared total healthcare costs (THCC) for the year before the ICS use increase (baseline cost) with the year after (outcome cost). The analysis, after adjustments for age, sex, baseline asthma control status and baseline THCC, showed outcome cost increases for each treatment regimen, with FP costing pounds Sterling 33.00 (-pounds Sterling 2.53 to pounds Sterling 68.54) more than QVAR(R) and BDP costing pounds Sterling 22.51 (-pounds Sterling 43.96 to -pounds Sterling 1.06) less than QVAR(R). The mean outcome cost for QVAR(R), at pounds Sterling 547.94 was intermediate between that of FP (pounds Sterling 580.94) and of BDP (pounds Sterling 525.43). Asthma control rates were higher in the QVAR(R) group, making the odds ratio (OR) for successful asthma control lower for BDP-CFC (OR=0.85; 95% CI, 0.76-0.96) and for FP (OR=0.91; 95% CI, 0.75-1.10) as compared with QVAR(R).

About GPRD

The GPRD is the world's largest computerized database of anonymized longitudinal medical records from primary care. Data are being collected on over 3.6 million active patients (approximately 13 million totals) from around 450 primary care practices throughout the UK. It is the largest and most comprehensive source of data of its kind and is used worldwide for research by the pharmaceutical industry, clinical research organizations, regulators, government departments and leading academic institutions. GPRD is considered the gold standard of research databases.

About QVAR(R)

QVAR(R) (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR(R) is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR(R) may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information

QVAR(R) is not a bronchodilator and is not indicated for relief of acute bronchospasm. Common side effects associated with the use of QVAR(R) and placebo in clinical trials includes, but is not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively). Caution: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information). A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment.

About Teva

Teva Pharmaceutical Industries Ltd., (Nasdaq: TEVA) headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.

SOURCE Teva Respiratory, a division of Teva Pharmaceutical Industries, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology: